Loading
Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medication specifically indicated for the treatment of molluscum contagiosum in individuals aged one year and older. Furthermore, the company leverages NITRICIL, an exclusive technological platform grounded in nitric oxide research. Established in 2002, this Durham, North Carolina-based firm was previously known as Channel Therapeutics Corporation, before rebranding to Pelthos Therapeutics Inc. in July 2025.
Previous close
$20.50
$0.00 · 0.00%
Regular session · ET · Market data may be delayed.
Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medication specifically indicated for the treatment of molluscum contagiosum in individuals aged one year and older. Furthermore, the company leverages NITRICIL, an exclusive technological platform grounded in nitric oxide research. Established in 2002, this Durham, North Carolina-based firm was previously known as Channel Therapeutics Corporation, before rebranding to Pelthos Therapeutics Inc. in July 2025.
Day range
Current $20.50
52-week range
Current $20.50
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
66
Undervalued
Sentiment
61
Bullish
Risk
80
High Risk
Momentum
50
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medication specifically indicated for the treatment of molluscum contagiosum in individuals aged one year and older. Furthermore, the company leverages NITRICIL, an exclusive technological platform grounded in nitric oxide research. Established in 2002, this Durham, North Carolina-based firm was previously known as Channel Therapeutics Corporation, before rebranding to Pelthos Therapeutics Inc. in July 2025.
Day range
Current $20.50
52-week range
Current $20.50
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 16.8M USD | — | — | — | — |
| Cost of goods sold | 9.37M USD | — | — | — | — |
| Gross profit | 7.43M USD | — | — | — | — |
| Research and development | 1.23M USD | 1.18M USD | 2.58M USD | 391.73K USD | 209.05K USD |
| Selling, general, and administrative | 37.08M USD | 6.39M USD | 4.28M USD | 1.93M USD | 629.95K USD |
| Operating expenses | 39.86M USD | 7.57M USD | 6.86M USD | 2.32M USD | 839K USD |
| Interest income | 5K USD | — | — | — | — |
| Interest expense | 3.01M USD | 786.39K USD | 518.51K USD | 140.43K USD | 253 USD |
| Depreciation and amortization | 2.29M USD | — | — | — | — |
| Operating income | −32.43M USD | −7.57M USD | −6.86M USD | −2.32M USD | −839K USD |
| Net income | −43.32M USD | −7.96M USD | −7.38M USD | −2.46M USD | −595.39K USD |
Company facts updated Oct 10, 2026.
Third-party consensus; not a GoAI recommendation.
Average target
$54.50
165.85% upsideLimited analyst sample: 3 ratings. Interpret the distribution with caution.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jul 2, 2025 | 1:10 | — | — |
Effective Jul 2, 2025
1:10
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
iShares Micro-Cap ETFIWCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
